GlycoMimetics/GLYC

$3.00

-1.96%
-
1D1W1MYTD1YMAX

About GlycoMimetics

GlycoMimetics, Inc. is a clinical-stage biotechnology company, which is focused on the discovery and development of glycomimetic drugs. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer, and infection. Its drug candidates include Uproleselan, GMI-1359, GMI-1687, and Galectin Antagonists. It is developing Uproleselan, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML). Its GMI-1359 targets both E-selectin and a chemokine receptor known as CXCR4. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. The Company is engaged in advancing other preclinical-stage programs, including small-molecule glycomimetic compounds that inhibit the protein galectin-3.

Ticker

GLYC

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Harout Semerjian

Employees

38

Headquarters

Rockville, United States

GlycoMimetics Metrics

BasicAdvanced
$186.74M
Market cap
-
P/E ratio
-$0.64
EPS
2.18
Beta
-
Dividend rate

What the Analysts think about GlycoMimetics

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 3 analysts.
155.67% upside
High $12.00
Low $3.00
$3.00
Current price
$7.67
Average price target

GlycoMimetics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-9.2M
12.2%
Profit margin
0%
-

GlycoMimetics Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 2.33%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.19
-$0.17
-$0.13
-$0.14
-
Expected
-$0.17
-$0.17
-$0.18
-$0.14
-$0.15
Surprise
14%
2%
-29.09%
-2.33%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell GlycoMimetics stock

Buy or sell GlycoMimetics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing